DC-CIK细胞联合治疗80例晚期肺癌的临床观察

摘要

目的：观察DC-CIK细胞联合治疗晚期肺癌的疗效。方法：入组患者为我院2011年4月-2013年4月80例晚期肺癌均接受手术、化疗后复发者，已经诊断Ⅳ期不宜给予手术、化疗等其它抗肿瘤治疗。随机分成DC-CIK治疗组，中药扶正等药物抗肿瘤治疗的对照组。观察2组的临床缓解率、临床获益率、无进展生存期、中位生存期及1年生存率。结果：临床缓解率、临床获益率、无进展生存期、中位生存期及1年生存率均是DC-CIK治疗组优于对照组。结论：DC细胞联合CIK细胞能提高癌症患者免疫功能，改善临床症状，延长生存期。%Objective:To study the effect of combined DC-CIK cells therapy for advanced lung cancer. Meth-ods:The 80 patients recruited in our hospital from 2011 April to 2013 April,whose tumor relapsed after operation and chemotherapy,and these patients had the diagnosis of stage IV which was not suit to operation and chemotherapy. The patients were divided into the DC-CIK therapy group and the control group for anti-tumor treatment by Chinese medicine therapy. Response rate,clinical benefit rate,median survival time,progression-free survival time and 1 year survival time were observed. Results:Total efficiency of DC-CIK therapy group was better than the control group in response rate,clinical benefit rate,progression-free survival time and 1 year survival time. Conclusion:DC-CIK cells therapy can improve cancer patients′immune function,clinical symptoms and prolong the survival time.